New York State Common Retirement Fund Cuts Position in Illumina, Inc. (NASDAQ:ILMN)

New York State Common Retirement Fund decreased its holdings in Illumina, Inc. (NASDAQ:ILMN) by 24.5% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 126,859 shares of the life sciences company’s stock after selling 41,251 shares during the period. New York State Common Retirement Fund owned approximately 0.08% of Illumina worth $17,664,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of ILMN. Vanguard Group Inc. raised its holdings in Illumina by 15.0% in the third quarter. Vanguard Group Inc. now owns 17,967,758 shares of the life sciences company’s stock valued at $2,466,614,000 after buying an additional 2,336,935 shares during the period. Barclays PLC grew its position in Illumina by 120.0% in the third quarter. Barclays PLC now owns 1,768,355 shares of the life sciences company’s stock valued at $242,758,000 after acquiring an additional 964,709 shares in the last quarter. abrdn plc grew its position in Illumina by 764.9% in the fourth quarter. abrdn plc now owns 339,023 shares of the life sciences company’s stock valued at $47,206,000 after acquiring an additional 299,827 shares in the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its position in Illumina by 245.7% in the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 417,876 shares of the life sciences company’s stock valued at $57,366,000 after acquiring an additional 296,990 shares in the last quarter. Finally, Bank of New York Mellon Corp grew its position in Illumina by 6.6% in the third quarter. Bank of New York Mellon Corp now owns 3,648,935 shares of the life sciences company’s stock valued at $500,926,000 after acquiring an additional 225,074 shares in the last quarter. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Insider Buying and Selling at Illumina

In related news, CEO Jacob Thaysen acquired 7,330 shares of the business’s stock in a transaction that occurred on Thursday, February 22nd. The shares were acquired at an average cost of $135.29 per share, for a total transaction of $991,675.70. Following the completion of the purchase, the chief executive officer now directly owns 14,861 shares in the company, valued at $2,010,544.69. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. 0.17% of the stock is currently owned by company insiders.

Illumina Stock Performance

ILMN stock opened at $122.28 on Monday. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.29 and a current ratio of 1.66. The stock has a market capitalization of $19.47 billion, a price-to-earnings ratio of -16.66 and a beta of 1.19. Illumina, Inc. has a 1 year low of $89.00 and a 1 year high of $213.91. The stock’s fifty day moving average is $131.51 and its two-hundred day moving average is $127.24.

Illumina (NASDAQ:ILMN) last posted its earnings results on Thursday, February 8th. The life sciences company reported $0.14 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.01 by $0.13. The company had revenue of $1.12 billion for the quarter, compared to analysts’ expectations of $1.09 billion. Illumina had a positive return on equity of 2.20% and a negative net margin of 25.78%. The firm’s quarterly revenue was up 3.6% compared to the same quarter last year. During the same period last year, the business posted $0.14 earnings per share. On average, research analysts predict that Illumina, Inc. will post 0.91 EPS for the current year.

Analyst Ratings Changes

Several analysts have issued reports on ILMN shares. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $253.00 price objective on shares of Illumina in a research report on Tuesday, April 9th. TD Cowen downgraded shares of Illumina from an “outperform” rating to a “market perform” rating and set a $144.00 price objective for the company. in a research report on Thursday, January 4th. StockNews.com raised shares of Illumina from a “hold” rating to a “buy” rating in a research report on Friday, February 16th. HSBC downgraded shares of Illumina from a “buy” rating to a “hold” rating in a research report on Tuesday, January 16th. Finally, Stephens reissued an “overweight” rating and set a $170.00 price target on shares of Illumina in a research report on Wednesday, April 10th. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $167.70.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.